Joshua Rottner

A partner in Goodwin’s Life Sciences group, Josh counsels high-growth life sciences, healthcare and technology companies from their formation through an initial public offering or M&A exit. Josh often serves as his clients’ outside general counsel, advising them on startup and formation matters, corporate governance, financing transactions, mergers and acquisitions, and other strategic transactions, working closely with his clients’ management teams and boards of directors to achieve their strategic goals.

In addition, Josh has extensive experience representing venture capital and growth equity funds in their portfolio company investments and acquisitions in the healthcare and technology industries. He also advises public companies in public offerings, Securities and Exchange Commission periodic reporting and compliance, and M&A transactions.

Josh’s selected representative company clients include:

Life sciences and healthcare

• Abcuro, a biotechnology company developing monoclonal antibodies designed to selectively target highly cytotoxic T cells in autoimmune diseases*
• Brave Bio, an adeno-associated virus gene therapy company treating central nervous system diseases*
• Celero Systems, a company developing a revolutionary digital health platform to monitor, diagnose and treat life-threatening conditions*
• Clarity Software Solutions, a data- and technology-driven provider of member communication solutions for health insurance payers*
• Common Sensing, a developer and manufacturer of data-driven hardware and software solutions for people using injectable medicine*
• Dyno Therapeutics, a company pioneering machine learning to open new frontiers for gene therapy*
• FireCyte Therapeutics, a company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye*
• Groups Recover Together, a provider of respectful, accessible and affordable opiate addiction treatment*
• InnDura Therapeutics, a biotechnology company developing a new class of cell therapies with enhanced killing and reduced exhaustion (compared to other Chimeric antigen receptor-armed cell therapies)*
• Incysus Therapeutics, a biotechnology company advancing a unique and innovative approach toward cancer treatments*
• Pretzel Therapeutics, a company developing groundbreaking therapies based on a deep mechanistic understanding of mitochondrial biology*
• Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic health conditions in pets*
• Tarveda Therapeutics, a biopharmaceutical company developing cancer medicines*
• TruDataRx, a company using objective clinical data to help fiduciaries improve the clinical effectiveness and reduce the costs of pharmacy benefits for its employees, members and health plan*
• Violet Therapeutics, a company utilizing novel proprietary platforms for the identification of cell-cell interaction mechanisms*

Technology

• AirWorks Solutions, a provider of artificial intelligence solutions for engineering*
• Covalent Networks, a developer of workforce qualification management software in dynamic industrial environments*
• Neurala, a pioneer in vision inspection AI software*
• Neurable, a creator of full-stack neurotechnology tools that interpret human intent, measure emotion and provide telekinetic control of the digital world*
• Running Tide Technologies, a global ocean health company rebalancing the carbon cycle*
• YOTTAA, a software company helping ecommerce brands improve the shopper experience and increase conversions through websites that load fast and offer engaging functionality*

Josh’s selected investor representations include:

• Alpha Wave Global*
• Altimeter Capital*
• Bessemer Venture Partners*
• General Catalyst*
• Guidepost Growth Equity*
• New Enterprise Associates*
• Seae Ventures*
• Unbundled Capital*
• Wellington Management Company*
• WuXi Healthcare Ventures*

*Denotes experience prior to joining Goodwin

Prior to joining Goodwin, Josh was a partner at Cooley.